

Intacs. The group plans to seek FDA approval to use Intacs to treat LASIK patients. Potential LASIK-related applications include treating people with post-LASIK complications such as corneal thinning, undercorrection and visual regression. Also included in a second study would be people with severe myopia who might be treated with a combination of LASIK and Intacs to limit surgical ablation of the cornea. Subject to FDA approval, a proposed third study would explore the use of Intacs in treating glare, halos, starbursts, decentered laser ablations and other LASIK complications.

The initial keratoconus feasibility study will be conducted at four CRS-affiliated clinical sites. These include the Eye and Ear Institute at the University of Pittsburgh; Jules Stein Eye Institute at the University of California-Los Angeles; Nevyas Eye Associates/Delaware Valley Laser Surgery Institute, Bala Cynwyd, Pa.; and Lasersight Eyecare Medical Group Inc., Santa Barbara, Calif.